Evofem Biosciences (Evofem Biosciences) EPS (Basic) : $7.81 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Evofem Biosciences EPS (Basic)?

Evofem Biosciences's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.26. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $7.81.

Evofem Biosciences's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.56. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.74.

Evofem Biosciences's EPS without NRI for the three months ended in Dec. 2023 was $-0.65. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -8.83.

During the past 3 years, the average EPS without NRI Growth Rate was 98.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 87.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 57.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, Evofem Biosciences's highest 3-Year average EPS without NRI Growth Rate was 98.00% per year. The lowest was -103.90% per year. And the median was 36.00% per year.

Evofem Biosciences EPS (Basic) Historical Data

The historical data trend for Evofem Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evofem Biosciences EPS (Basic) Chart

Evofem Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-3,731.23

-3,974.98

-2,953.75

-167.42

10.36

Evofem Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-11.66	-1.85	-5.43	15.34	-0.26

Evofem Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Evofem Biosciences's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(52.979	-	2.984)	/	4.827
	=	10.36

Evofem Biosciences's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.114	-	0)	/	20.008
	=	-0.11

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.81

Evofem Biosciences (OTCPK:EVFM) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Evofem Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Evofem Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Evofem Biosciences (Evofem Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evofem Biosciences Inc (OTCPK:EVFM) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122

Website

https://www.evofem.com

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

Executives

Yan Zhang	officer: Chief Financial Officer	6166 TIKI CT, SAN DIEGO CA 92130
Kim P. Kamdar	director, 10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Jenny C. Yip	director	12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130
Atkinson Katherine Cocca	officer: Chief Commercial Officer	12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130
Saundra L Pelletier	director, officer: Chief Executive Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: General Counsel and Secretary	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Justin J. File	officer: Chief Financial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Anthony Stephen O'brien	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Russell Barrans	officer: Chief Commercial Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130
Lisa Dale Rarick	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130
William Walmsley Hall	director	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130
Invesco Ltd.	10 percent owner	1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309
Link Fund Solutions Ltd	10 percent owner	65 GRESHAM STREET, LONDON X0 EC2V 7NQ
Acacia Research Corp	10 percent owner	767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017
Kelly Culwell	officer: Chief Medical Officer	C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130